“We are delighted to welcome Thomas to Sciety. His extensive experience in building and developing international life science companies, combined with his background as an investor, will be highly valuable to us. We look forward to drawing on his perspective and expertise as we continue to grow the business,” says Anna Sundin, CEO, Sciety.

Thomas Eldered

Eldered began his career at Pharmacia, where he held several senior positions. In the 1990s, he co-founded Recipharm and, as CEO, built it into one of the world’s leading contract manufacturers of pharmaceuticals. The company was listed on Nasdaq Stockholm in 2014, and by the end of his tenure as CEO it had annual sales of approximately SEK 11 billion, close to 9,000 employees, and operations in ten countries.

Related article

Exclusive interview: Thomas Eldered predicts 2024

Personalized medicine, weight loss remedies and new treatments for widespread ailments are among the rising areas of high interest in the biotechnology and therapeutic arenas, according to executive chairman of Flerie Invest, Thomas Eldered.

In 2011, Eldered founded Flerie, which is now listed on Nasdaq Stockholm and holds an investment portfolio valued at approximately SEK 2.7 billion. He serves as Flerie’s executive chairman.

“There are many promising life science companies in the Nordics with great development potential, but access to capital and the right expertise is often what determines whether they succeed. Sciety plays an important role in connecting these companies with investors and supporting their growth. I look forward to sharing my experience and contributing to Sciety’s continued work,” says Thomas Eldered.